ABSTRACT
This chapter describes trade name, classification, approved Indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, and clinically significant drug interactions of Serotonin. Adjunctive pharmacotherapy for the symptomatic management of: anxiety Disorders: obsessive-compulsive disorder, and mood disorders, depressive disorders: major depressive disorder. Most patients will require long-term SSRI pharmacotherapy for the symptomatic management of depression or obsessive-compulsive disorder. The exact mechanism of antidepressant, anti-obsessional, and other related actions of the SSRIs has not yet been fully determined. The SSRIs appear to act at both pre- and post-synaptic neuronal sites by selectively inhibiting the re-uptake of serotonin. Abrupt discontinuation of the SSRIs may result in a withdrawal syndrome. The serotonin syndrome also may occur with concurrent SSRI and other serotonergic pharmacotherapy. The SSRIs are associated with the fewest and lowest incidence of ADRs when compared to the other available antidepressants.
